The U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral pill for the treatment of moderate-to-severe plaque psoriasis. Developed by Johnson & Johnson in collaboration with Protagonist Therapeutics, this once-daily pill is a targeted oral peptide and the first oral IL-23 receptor blocker approved for psoriasis. The approval is seen as a potential game-changer in the management of this debilitating skin condition, providing hope to millions of patients. With this new treatment option, J&J aims to compete with existing treatments such as AbbVie’s Skyrizi. The approval has been met with positive sentiments in the pharmaceutical sector, indicating a promising future for the company and the psoriasis treatment landscape.